FOR RESEARCH USE ONLY
Early human researchCognitive research

Semax

ACTH-fragment analogue researched for neuroprotection, focus and BDNF/NGF upregulation.

01BDNF & NGF02Ischaemic injury03Attention & cognition
Molecular signature / semax
Structural identity

Synthetic heptapeptide based on an ACTH fragment

Also known as

ACTH(4-10) analogue · Met-Glu-His-Phe-Pro-Gly-Pro

Research-use context

In-vitro and laboratory information only. No human-use recommendation.

Guide contentsOpen in calculator
Section 01

Compound briefing

Semax is a synthetic heptapeptide analogue of ACTH(4-10), developed in Russia and used clinically there for stroke recovery, cognitive enhancement and optic-nerve disorders. It is one of the most extensively studied nootropic peptides, with documented neuroprotective and neurotrophic effects.

The research question

Semax research spans ischaemic injury, neurotrophic signalling and attention. Outcomes in neurological injury models cannot simply be transferred to healthy-subject cognitive research.

Section 02

Mechanism & research themes

Upregulates BDNF and NGF expression, modulates dopaminergic and serotonergic transmission, and inhibits enkephalin-degrading enzymes. Demonstrates neuroprotective effects via reduced excitotoxicity and oxidative stress.

01

Significant neuroprotection in ischaemic stroke research

02

Sustained BDNF and NGF upregulation supporting neuroplasticity

03

Improved attention, working memory and executive function

04

Improved recovery outcomes in optic-nerve and CNS-injury research

05

Modulation of dopaminergic systems supporting motivation and mood

06

Favourable safety profile in Russian clinical use

These are research themes reported across the literature, not established benefits or indications.

Section 03

Evidence assessment

Early human research

Clinical use and trials are reported mainly in Russian-language literature. Broader conclusions require independent replication and clear separation of neurological indications from general cognitive claims.

What to look for

Controlled design, a defined preparation, clinically relevant endpoints and independent replication carry more weight than a single mechanism study.

What not to assume

A plausible pathway does not establish efficacy. Results across different routes, formulations and populations are not automatically interchangeable.

Section 04

Protocol literature

Commonly referenced research protocols use 250–600mcg intranasally 1–3× daily, or subcutaneously at similar doses. Cycles typically run 2–4 weeks with breaks. Higher doses (up to 1200mcg/day) appear in stroke-recovery research.

Reported persistence

Plasma half-life is very short (minutes), but CNS effects persist for hours due to BDNF/NGF upregulation cascades.

Calculator starting point

0.3 mg per reference dose

5 doses per week · 4-week cycle

2 mL default reconstitution volume

300 mcg–1 mg SC or intranasal, short cycles.

Calculator defaults are editable mathematical reference values, not dosing advice. Verify all calculations independently.

Calculate Semax
Section 05

Laboratory handling

Reconstitution reference

Reconstitute a 5mg vial with 2–5mL bacteriostatic water (or sterile saline for intranasal). Swirl gently.

Storage reference

Lyophilised: 2–8°C, stable 18–24 months. Reconstituted: 2–8°C, protect from light, use within 30 days.

Minimum documentation standard

  • Record the lot identifier and review its matching analytical documentation.
  • Use aseptic technique and record diluent, final volume and calculated concentration.
  • Label preparation date, storage conditions and any light or freeze–thaw restrictions.
  • Inspect before each use and investigate unexpected colour, clarity or particulate changes.
Section 06

Limitations & safety

L1

Most efficacy data is from Russian clinical literature; Western RCT data is limited.

L2

Overstimulation, irritability or headache reported at higher doses.

L3

Intranasal administration may cause transient nasal irritation.

Research use only

This field note is an educational literature summary, not medical advice or a recommendation for human use. Safety statements are limited by the quality and duration of the available evidence.

Continue reading

Related field notes

Back to all field notes

Welcome to HV Labs

Please confirm your age to continue.

For research use only